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ABSTRACT
Objective: Many patients have medically unexplained physical symptoms (MUPS); some of them attri-
bute their health complaints to dental amalgam fillings. The aim of this study was to assess the valid-
ity and responsiveness of General Health Complaints index (GHC-index) for measuring the symptom
load in MUPS patients compared to the widely used symptom outcome measure, Giessen Subjective
Complaints List (GBB-24).
Methods: Three outcome measures – GHC-index, GBB-24, and Munich Amalgam Scale (MAS) – were
administered at baseline and 12months after removal of all dental amalgam restorations. The validity
and responsiveness of these symptom measures were tested against external anchors: bodily distress
syndrome (BDS), SF-36 vitality, and visual analogue scale (VAS). We tested both convergent and known
group validities. We also examined the predictive validity and responsiveness to changes for
each instrument.
Results: All the main outcome measures showed evidence of convergent and known group validities.
The GHC-index, GBB-24 and MAS were all able to detect the anticipated differences in BDS and Energy.
But the GBB-24 was more efficient in discriminating the BDS compared with the GHC-index (relative effi-
ciency: RE ¼ 0.69; 95% CI: 0.41–0.96) and MAS (RE ¼ 0.59; 95% CI: 0.32–0.86). Each main outcome vari-
able revealed good predictive validity for vitality (standardized coefficient: b 0.71 and R2  0.50).
Moderate to high sensitivity to change over time was demonstrated, with GHC-index performing better.
Conclusion: The GHC-index is a valid and responsive instrument for assessing symptom load in MUPS
patients attributing their health complaints to amalgam fillings and undergoing amalgam removal.
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Patients with medically unexplained physical symptoms
(MUPS) suffer from persistent health complaints that cannot
be sufficiently explained by observable physical pathology
despite intensive diagnostic efforts [1,2]. Studies suggest
between 3% and 50% of primary care patients present with
MUPS [3–6]. Such variations in the prevalence of MUPS could
be due to differences in the diagnostic criteria [3]. Evidence
suggests that MUPS exists on a continuum of severity, rang-
ing from patients with transient, mild symptoms to those
with multiple, debilitating unexplained symptoms [7,8], con-
stituting a major burden with considerable societal costs of
direct healthcare or lost productivity. In a Dutch study, the
sum of direct healthcare and productivity-related costs were
estimated at e6,816 per patient per year [9]. The costs attrib-
utable to MUPS due to lost productivity alone is over £5
billion per annum to the UK economy [10], and e7645 per
patient per 6-month in Germany [11].
The assessment of the burden of MUPS is important in
clinical settings and in the general population for identifying
individuals at risk as well as for evaluating treatment effects.
Thus, well validated measurement tools are needed. The
choice of functional measure for use as a primary outcome
in studies of MUPS patients is challenging due to few suit-
able instruments. The choice of instrument depends on the
symptoms and outcomes of interest and the psychometric
properties of the instruments [12]. Although a number of
outcome measures have been developed to measure the
patient’s own perception of symptoms and functional activ-
ities, they varied regarding usability and burden to partici-
pants as well as relevance to a variety of populations [13].
Some patients with MUPS attribute their health com-
plaints to dental amalgam restorations. In this patient group,
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there is some evidence of symptom relief after removal of
amalgam [14,15]. Among MUPS symptoms, neurological
symptoms such as fatigue and dizziness are the most
reported complaints attributed to dental amalgam [16]. Pain
in muscles and joints, and headache as well as gastrointes-
tinal symptoms are also commonly reported [17]. A General
Health Complaints index (GHC-index), which includes com-
mon general health complaints in patients referred to the
Norwegian Dental Biomaterials Adverse Reactions Unit, has
widely been used in Norway [14,15,18,19]. The GHC-index
was intended to capture these major symptoms, but its val-
idity and responsiveness have so far not been formally
investigated.
Thus, the aim of this study was to assess the validity and
responsiveness of GHC-index in MUPS patients who attrib-
uted their health complaints to amalgam restorations in rela-
tion to a widely used outcome measure for physical
complaints of different causes – the 24-item Giessen
Subjective Complaints List (GBB-24) [20]. To test the consist-
ency of our results, a comparison will also be made with an
instrument previously used in a German intervention study
of patients with amalgam-attributed health complaints [21],
which we refer hereafter as the Munich Amalgam
scale (MAS).
Methods
Study design and data
The analysis was based on a longitudinal prospective cohort
study in Norway on MUPS patients who had all amalgam fil-
lings removed. The study was designed using a non-equiva-
lent comparison-group design with pre- and post-test, where
three groups were recruited separately. The main target
group consisted of patients with MUPS, which they attrib-
uted to dental amalgam restorations and who wished to
have their amalgam fillings removed (Amalgam cohort;
n¼ 32). The second group included patients with MUPS
recruited from general practice without symptom attribution
to amalgam fillings (MUPS cohort; n¼ 28). The last group
was participants who identified themselves as healthy
(Healthy cohort; n¼ 19). This analysis is based on the
Amalgam cohort. Initially, 49 participants were assessed for
inclusion in the Amalgam cohort, of which 12 subjects did
not fulfil the eligibility criteria and 5 did not complete the
amalgam removal. Thus, a total of 32 participants were avail-
able for the follow-up analysis. Detailed recruitment proce-
dures and eligibility criteria were reported elsewhere [14, 22].
The research is registered at ClinicalTrials.gov. Identifier:




Data for three health complaint measures were collected at
baseline, and 12months after removal of amalgam fillings:
General health complaints index (GHC-index). The GHC-
index consists of 12 items: musculoskeletal complaints,
gastrointestinal complaints, cardiovascular complaints, skin
problems, complaints related to eyes/sight, complaints
related to ears/hearing/nose/throat, tiredness, dizziness,
headaches, memory problems, difficulty concentrating, and
anxiety/depression. For each item, symptom intensity is
assessed on a numeric rating scale from 0 (no symptoms) to
10 (worst imaginable symptoms). The sum score for the 12
items ranges from 0 to 120 [19], where lower scores indicate
less health complaints. Negative change scores represent
improvement.
Health complaints according to the GBB-24. The GBB-24
consists of 24 different health complaints, each rated on a
five point severity scale: 0 (not at all), 1 (slightly), 2 (some-
what), 3 (considerably) and 4 (very much) [20]. The com-
plaints are grouped and summarized into four subscales,
each with six complaints: Cardiovascular complaints, gastro-
intestinal complaints, musculoskeletal complaints, and exhaus-
tion. In this analysis, the scores of the 24 single complaints
were summed up in a total score (‘complaints load’) ranging
from 0 to 96 where 0 is no complaints at all while 96 repre-
sent all listed complaints at highest severity. Like the GHC-
index, negative change scores in GBB-24 represent
improvement.
Munich amalgam scale (MAS). MAS is a symptom list with
50 items, each with four intensity levels ranging from 0 (not
present) to 3 (strong intensity) [21]. The total theoretical
summary score is ranging from 0 (no symptom) to 150 (all
symptoms of strong intensity).
Anchors
For purposes of examining the validity of GHC-index in
MUPS patients attributing their health complaints to amal-
gam fillings, we used the following variables as external
anchors: Bodily Distress Syndrome (BDS) checklist, the Short
Form 36-questionnaire (SF-36) Vitality subscale, the Visual
Analogue Scale of the EQ-5D instrument (VAS) and the
Cantril Ladder of Life Scale (CL) as a measure of life satisfac-
tion. These anchors are selected based on the assumption
that they have some relationship with the main out-
come measures.
BDS checklist. We applied the BDS checklist, which measures
similar daily bothersome physical symptoms such as MUPS,
as the main external anchor against which the main out-
come variables were compared. The BDS checklist starts with
the question ‘have you been bothered by…’ followed by a
list of 25 symptom items measured on a 5-point Likert scale
from 0 (‘not at all’) to 4 (‘a lot’) [23]. We calculated the sum
score by adding the single item scores from the 25 items
(ranging from 0 to 100). A recent study validated the BDS
checklist total sum score as a measure of symptom burden
and illness severity, establishing the usefulness of the BDS
checklist in both clinical practice and epidemiological
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research [24]. We also used the BDS as a binary indicator
variable (no BDS versus moderate to severe BDS). We
denoted the continuous total sum score of BDS as BDSC to
distinguish it from binary BDS.
SF-36 vitality subscale and energy item. One of the most
frequent symptoms reported by MUPS patients is fatigue
[19]. To capture this, we used the Vitality scale of the SF-36
instrument [25] as an external anchor against which we
tested the validity of the main outcome measures. The
Vitality scale assesses energy and fatigue to capture differen-
ces in quality of life, and is based on four questions: How
much of the time during the past 4weeks (i) did you have a
lot of energy? (ii) have you felt full of life? (iii) did you feel
worn out? and iv) did you feel tired? Each question has a five-
point scale ranging from none of the time to all of the time.
The total summary score ranges from 0 to 100, with lower
score indicating less vitality. In general, Vitality is hypothe-
sized to be highly associated with the main outcome varia-
bles since they measure similar clinical phenomena (fatigue
and tiredness). To test the discriminative ability of each out-
come variable, we also considered the first question, Energy,
as a categorical variable at follow-up.
VAS. To check the consistency of our results, we also used
VAS as an external anchor against which the main outcome
variables were compared. VAS records the respondent’s self-
rated health on a vertical scale, where the end points are
labelled 0 (‘the worst imaginable health’) and 100 (‘the best
imaginable health’). The respondents were asked to choose
on any point of the VAS scale that best represents their
health. The VAS scores were summarized and analyzed as
continuous data.
CL life satisfaction. The CL is a self-reported measure of life
satisfaction in response to the question: Please imagine a lad-
der with steps numbered from zero at the bottom to ten at the
top. Suppose we say that the top of the ladder represents the
best possible life for you and the bottom of the ladder repre-
sents the worst possible life for you. On which step of the lad-
der do you feel you personally stand at the present time? CL is
treated as a continuous variable. In the present study we
used a scale from 1 (worst possible life) to 10 (best pos-
sible life).
Validation analysis
A measurement tool is said to be valid if it measures what it
intends to measure. However, it is difficult to ascertain that a
measure is valid in the absence of a gold standard measure
against which we compare [12], and, thus, validation is a pro-
cess of hypothesis testing to increase confidence that a
measurement scale has the properties that would be
expected if it was valid. Validation tests are variously classi-
fied; we here present tests of convergent, known group and
predictive validity, as well as responsiveness over time and
of reliability test.
Internal consistency and convergent validity
Internal consistency was tested using Cronbach’s alpha (a). It
is a statistic commonly used to assess whether instruments
that have been constructed measures what they intend to
measure [26]. This statistic was estimated for each of the
main outcome measures at both baseline and follow-up. The
commonly used cut-off points for inferring adequate internal
consistency was: a> 0.70 [26,27].
Convergent validity assesses the strength of the relation-
ship between measures. To determine the degree to which
the symptom measures are related to other measures of simi-
lar construct, convergent validity was examined by comparing
them to the scores reported on the BDSC, Vitality, VAS, and CL
at follow-up using Spearman’s correlation coefficients (rho, q).
We expected strong correlations between the BDSC and the
symptom measures, as well as the Vitality. Correlation analysis
can indicate the degree to which instruments are measuring
related factors. Absolute correlation strength is classified as
weak (<0.3), moderate (0.3 to <0.5), and strong (>0.5) [28].
Known-group validity
Known-group validity assesses the extent to which instrument
scores differ across groups that are expected to differ and was
used to examine the discriminative validity of each of the
symptom measures. The BDS and the SF-36 item Energy were
used as external anchors. Subjects with poorer health status
were hypothesized to have lower scores on the main outcome
measures. The Kruskal–Wallis test and relative efficiency (RE)
were used to explore the known-group validity of different
symptom measures. The RE statistic could be defined as the
ratio of either chi-squared (v2) statistics or squared t statistics,
and can be used to evaluate the sensitivity of different main
outcome measures to known group differences [29]. Here, RE
is defined as the ratio of v2, where GBB-24 was used as a ref-
erence in the denominator. Thus, a RE value less than 1
implies that the GBB-24 is more able to discriminate between
meaningfully different groups (e.g. level of Energy or BDS),
and the inverse is true for an RE value of greater than 1.
Predictive validity
Predictive validity was tested by the ability of GHC-index to
predict changes in the symptom or health predicted by
other instruments (GBB-24 and MAS). We applied binary
logistic regression models to evaluate the ‘predictive validity’
of each symptom measure as predictor of unfavourable out-
comes at follow-up: (a) low self-rated health; and (b) moder-
ate/severe BDS type. Let Yi denote the binary independent
variable (e.g. 1 for ‘low self-rated health’ and 0 for ‘high self-
rated health’), and Xi is one of the main outcome measures.
The model is given by:
P Yi ¼ 1ð Þ ¼ pi ¼ exp b0 þ b1Xið Þ1þ expðb0 þ b1XiÞ
þ ei,
where pi denote the maximum likelihood of the success
probabilities, b0 and b1 are constant parameters to be esti-
mated, and ei is the error term.
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The increased odds of having an unfavourable outcome
for a one SD change in each of the symptom measures
(standardized coefficient of X) were calculated to facilitate
the comparison of the predictive effects of each instrument
(GHC-index, GBB-24 and MAS) measured in different scales.
The standardization of X alone produces the relative import-
ance of X. We also reported the coefficient of discrimination
(D) for logistic regression [30], which is closely related to the
classical coefficient of determination (R2) in linear regression.
It is given by the difference between the mean predicted
probabilities for successes (p̂1 ) and failures (p̂0 ), and
hence, used as a standard measure of explanatory power
[28]. That is, D ¼ p̂1  p̂0 :
Furthermore, we applied ordinary least square linear
regression models to determine the ability of each measure
to predict vitality as well as the bodily distress syndrome:
Yi ¼ aþ bXi þ ei: Here, Yi is a continuous response variable
(measured by Vitality or BDSC), and all others are as defined
before. In addition to the standardized b coefficients, the
amount of total variance explained (R2) in Vitality or BDSC
was used to compare the predictive validity across main out-
come measures.
Responsiveness
Responsiveness is defined as the degree to which a measure
detects meaningful change. Meaningful change can be deter-
mined using either distribution-based methods (statistical distri-
butions of change and associated reliability) or anchor-based
methods (external criterion of change reflecting a patient or
clinician’s perspective [31]. In the present study, we calculated
the following metrics to measure the responsiveness of the
main outcome variables: mean change score (MCS), effect size
(ES), standard response mean (SRM), standard error of measure-
ment (SEM) and minimal detectable change (MDC).
Effect size and standard response mean. To provide a met-
ric of responsiveness independent of direction, we computed
absolute ES for each outcome measure: ES¼ abs((M2M1))/
S1, where M2 is the mean score at follow-up, M1 is the mean
score at baseline, and S1 is the standard deviation (SD) of
the baseline. The SRM is also a measure of effect size index
used to gauge the responsiveness of scales to clinical
change. The SRM is computed in a similar way as the ES but
using the standard deviation of the mean change in the
denominator. The thresholds for interpreting ES values are:
small (0.20), medium (0.50), and large (0.80) [28]. The same
thresholds applied for interpreting SRM.
Standard error of measurement. The SEM is the variation in
measured symptom attributed to the unreliability of out-
come measures, where a change smaller than the value of
SEM would likely be due to measurement error instead of a
true observed change [32]. The SEM is a theoretically fixed
test characteristic of any measure and not sensitive to the
number of participants in a study [33]. It is calculated as:
SEM ¼ S1(1  a), where a is the reliability coefficient. In this
analysis, the value for the reliability coefficient was estimated
by the internal consistency reliability, usually referred to as
Cronbach’s alpha (a), as suggested in the literature [34,35].
For the derivation of SEM, the value of a at follow-up period
was used.
There is no standard threshold value for SEM to indicate
an individual’s score change as the smallest meaningful
change, though ±1 SEM (equivalent to 63% confidence inter-
val) is a frequently used threshold [36]. However, a more
conservative criterion of ±1.645 SEM could be considered as
the safest threshold for identifying statistically detectable
individual score change, which is equivalent to 90% confi-
dence interval for SEM [36,37]. We used this conservative cri-
terion (±1.645SEM). Thus, SEM provides a measure of
variability and is primarily used to compute the minimally
detectable change (MDC) described below.
Minimal detectable change. The MDC is the minimum
amount of change in a patient’s score that ensures the
change is not the result of measurement error [37]. It is cal-
culated in terms of confidence of prediction, and hence,
MDC scores with 90% confidence (MDC90) were calculated
as: SEMZ902, where z is the z-value for the 90% confi-
dence level [38]. The multiplier of 2 is to account for the
additional uncertainty introduced by using different scores
from measurements at 2 time points – baseline and follow-
up. The MDC90 corresponds to the smallest amount of
change that falls outside of measurement error. The percent-
age of participants who demonstrated a change the MDC90
from baseline to follow-up was calculated for each measure.
Results
Reliability and convergent validity
Internal consistency and convergent validity of the main out-
come measures are reported in Table 1. Cronbach’s alpha for
internal consistency exceeded 0.80 for all main outcome vari-
ables, indicating excellent internal consistency. There was
evidence of strong convergent validity (q 0.50 and above)
for most combination of main outcome variables (GBB-24,
GHC-index, MAS) and anchor variables (BDSC, VAS, Vitality
and CL) at both baseline and follow-up. Exceptions were for
baseline observations between VAS and MAS and between
Vitality and MAS, where moderate convergent validity was
found. At follow-up, the highest correlation was observed
Table 1. Cronbach’s alpha for reliability test and correlation coefficients for
convergent validity.
Baseline Follow-up
GBB-24 GHC-index MAS GBB-24 GHC-index MAS
Internal consistency
Cronbach’s alpha (a) 0.93 0.87 0.92 0.92 0.86 0.89
Convergent validity (q)
BDSC 0.94 0.68 0.78 0.94 0.83 0.82
VAS 0.52 0.61 0.48 0.58 0.59 0.66
CL 0.59 0.60 0.54 0.67 0.62 0.67
Vitality 0.63 0.54 0.45 0.71 0.71 0.72
BDSc: Bodily distress syndrome (continuous), CL: Cantril ladder of life satisfac-
tion, GBB-24: 24-item Giessen subjective complaints list, GHC: General health
complaint, MAS: Munch amalgam scale.
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between GBB-24 and BDSC (q¼ 0.94), followed by the correl-
ation between GHC-index and BDSC (q¼ 0.83).
Known group validity
Known group validity is reported in Table 2, using Chi-
squared statistics and RE values. All outcome measures
showed evidence for known-group validity in detecting sig-
nificant (p< .001) differences between different status of
bodily distress syndrome and Energy, being used as the
known group variables. Compared to GBB-24, the GHC-index
and MAS were less efficient in discriminating BDS, with the
RE being significantly less than 1. However, there was no sig-
nificant difference across the outcome variables in discrimi-
nating patient ratings of their energy.
Predictive validity
Predictive validity is presented in Table 3. In the upper panel A,
the logistic regression models show the odds for an unfavour-
able outcome (low self-reported health, moderate to severe
BDS) for every 1 standard deviation (SD) increase in each of the
main outcome measures (GBB-24, GHC-index, MAS). All three
main outcome measures showed high predictive validity for
low self-rated health at follow-up, with GHC-index performing
best: a 1 SD increase in GHC-index leads to a 1.464 increase in
the log-odds of having low self-rated health. A similar pattern
was observed when using the coefficient of discrimination.
Similarly, high predictive validity for moderate to severe BDS
was observed across the main outcome measures, particularly
for GBB-24 as demonstrated by high coefficient of discrimin-
ation (0.746) and greater standardized coefficient. For instance,
a 1 SD increase in GBB-24 resulted, on average, in almost 6.8
increase in the log-odds of having bodily distress syndrome.
The corresponding values for 1 SD increase in GHC-index and
MAS were 2.803 and 1.741, respectively.
In the lower panel B of Table 3, predictive validity of
Vitality and BDSC in ordinary least square regression models
is presented. The three main outcome variables were equally
good predictors of Vitality, with similar standardized coeffi-
cients ( 0.71) and coefficient of determination (R2  0.50).
The predictive validity for BDSC was also comparable across
measures, with GBB-24 performing better. For instance, GBB-
24 was the best predictor, explaining the highest percentage
of the variability in BDSC checklist (R
2 ¼ 0.887), followed by
the GHC-index and MAS (R2 ¼ 0.696 and 0.666, respectively).
Responsiveness
Responsiveness, independent of direction, is presented in Table
4. Mean differences in the pre- and post-treatment scores were
significantly different for all three outcome measures (p< .001,
paired t-tests), with GHC-index showing the highest mean score
changes. Moderate to large absolute SMR were observed. For
the GBB-24 and MAS, moderate SRMs were observed (0.66 and
0.67, respectively). For the GHC-index, we observed large SRM
(0.81). All outcome measures revealed moderate ES, with GHC-
index performing best. The percentages of participants with
meaningful changes in either direction (a changeMDC90) for
each outcome measure varied between 43.8% (for GBB-24) and
56.3% (for GHC-index), with the GHC-index performing slightly
better than both MAS and GBB-24.
Discussion
This analysis contributes to the knowledge of the psycho-
metric properties of questionnaires used to measure
Table 2. Known group validity: Kruskal–Wallis statistics and relative efficiency
of GHC-index and MAS against GBB-24.
Kruskal–Wallis H test statistics v2ð3Þ
* RE (95% CI)
BDS
GBB-24 14.66 1 (Reference)
GHC-index 10.04 0.69 (0.41–0.96)
MAS 8.65 0.59 (0.32–0.86)
SF-36 energy
GBB-24 16.24 1 (Reference)
GHC-index 13.40 0.83 (0.50–1.15)
MAS 15.37 0.95 (0.53–1.36)
v23ð Þ: Chi-square statistic with 3 degrees of freedom, CI: 95% bootstrap confi-
dence interval (with 1000 iterations), BDS: Bodily distress syndrome, GBB-24:
24-item Giessen subjective complaints list, GHC: General health complaint,
MAS: Munch amalgam scale, SF-36 Energy: The Energy item of the subscale
Vitality of the SF-36 Health Survey.p< .01.
Table 3. Predictive validity of GBB-24, GHC-index and MAS: logistic and ordin-
ary least square regressions.
b se p-value CD/R2 ba
A. Logistic regression
Low self-reported health
GBB-24 0.086 0.038 .022 0.209 1.168
GHC-index 0.102 0.036 .005 0.255 1.464
MAS 0.096 0.036 .008 0.231 1.341
Moderate to severe BDS
GBB-24 0.503 0.212 .018 0.746 6.840
GHC-index 0.195 0.063 .002 0.380 2.803
MAS 0.125 0.060 .038 0.233 1.741
B. Ordinary least square regression
Vitality
GBB-24 1.151 0.243 <.001 0.505 0.711
GHC-index 1.080 0.239 <.001 0.496 0.705
MAS 1.134 0.196 <.001 0.514 0.717
BDSC
GBB-24 0.935 0.049 <.001 0.887 0.942
GHC-index 0.784 0.068 <.001 0.696 0.834
MAS 0.791 0.102 <.001 0.666 0.816
b: Unstandardized coefficient, b: Standardized coefficient, se: standard error of
b, CD: Coefficient of discrimination (for logistic regression), R2: Coefficient of
determination (commonly known as R-squared in linear regression), BDSC:
Bodily distress syndrome (continuous), GBB-24: 24-item Giessen subjective
complaints list, GHC: General health complaint, MAS: Munch amalgam scale,
Vitality: The Vitality subscale of the SF-36 Health Survey.
aWhile only X is standardized in logistic regression, both X and Y are standar-
dized in linear regression.
Table 4. Responsiveness of the symptom load measures: GHC-index, GBB-24
and MAS.
MCS (se) SRM (se) ES (se) SEM MDC90 %D > MDC90
GBB-24 7.1 (1.9) 0.66 (0.153) 0.51 (0.155) 3.88 6.36 43.8
GHC-index 12.8 (2.8) 0.81 (0.178) 0.72 (0.189) 6.57 10.81 56.3
MAS 10.3 (2.7) 0.67 (0.152) 0.58 (0.141) 5.83 9.60 46.9
MCS: Mean change score, GBB-24: 24-item Giessen subjective complaints list,
GHC: General health complaint, MAS: Munch amalgam scale, SRM: Standard
response mean, ES: Effect size, SEM: Standard error of measurement, MDC:
Minimal detectable change, se: Standard error.p< .001 for paired t-test.
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symptom load in MUPS patients. This is important for moni-
toring of symptom change in similar studies and other inter-
ventions on MUPS patients. The purpose of this study was,
therefore, to determine the validity and responsiveness of
GHC-index as compared with two other instruments – GBB-
24 and MAS – in patients with MUPS attributed to dental
amalgam restorations undergoing amalgam removal.
In our analyses, the GHC-index was an economical, reliable,
and valid symptom-specific instrument for the assessment of
MUPS in in patients who attribute their MUPS to amalgam
restorations. Cronbach’s alpha for GHC-index at both baseline
and follow-up was very high (a 0.80), indicating an excellent
internal consistency of the instrument. Similar results were also
obtained for the comparators (GBB-24 and MAS).
To our knowledge, this is the first analysis of the conver-
gent validity of GHC-index. In our study, the correlations of
the GHC-index with different anchors were all significant,
with Spearman rank order correlations greater than 0.50
both at baseline and follow-up. All outcome measures
showed strong correlation with the four anchors, particu-
larly with BDS that cover similar domains (q> 0.80), indicat-
ing that the instruments are measuring related aspects of
the same underlying construct. Furthermore, our results
confirmed the ability of the GHC-index to discriminate
between different severity levels of BDS and Energy in
MUPS patients with amalgam attribution, and so do the
GBB-24 and MAS. All outcome measures are similar in dis-
criminating the levels of Energy, and hence, there is no stat-
istical difference in their discriminative efficiency of Energy
in the present patient group. However, the GBB-24 was
more efficient than both GHC-index and MAS in discriminat-
ing the BDS severity levels. This is not surprising because
GBB-24 measures similar symptom loads with BDS as com-
pared to other instruments. In general, each symptom
instrument significantly discriminated between known
groups (e.g. by the levels of Energy or no BDS vs moderate
to severe BDS).
Our results from linear and logistic regression on predict-
ive validity of these instruments supported this finding. For
instance, the predictive ability of GBB-24 for BDS was 74.6%
using logistic regression and 88.7% for linear regression.
The respective values for GHC-index were 38.0% and 69.6%.
All symptom measures performed quite similarly in predict-
ing vitality. In the prediction of self-reported health, the
highest coefficient of discrimination is associated with the
GHC-index, indicating greater predictive validity by
this instrument.
Other measures of responsiveness produced consistent
results, with all main outcome measures showing good
responsiveness, with the GHC-index performing slightly bet-
ter. Large SRM was observed for GHC-index, indicating
stronger responsiveness compared to other measures.
Similarly, the percentages of participants demonstrating a
change the MDC90 was the largest for the GHC-index
(56.3%), followed by MAS (46.9%). This again shows the use-
fulness of specific questionnaires aimed at the actual
patient group.
Strengths of the study were extensive screening procedures
and high-quality treatment protocols for amalgam removal fol-
lowing generally accepted guidelines [14]. Furthermore, the
clinical screening and examination performed by dentists and
additional information from general practitioners limited the
probability that the presence of health complaints could be
explained by other diseases. Finally, we addressed both validity
and responsiveness with multiple approaches and several alter-
native anchors that enable us to confirm the consistency of
our results.
Some limitations of this study must be considered. Due to
the small sample size, variability in parameter estimates were
relatively wide. Nonetheless, the presence of statistically sig-
nificant results indicate that the study provided good evi-
dence about the reliability and usefulness of the instruments
applied. The patients in the amalgam cohort had to send an
application to the study office to be included in the study
and their inclusion in the study was subject to several selec-
tion criteria, including the desire to have their amalgam
restorations removed [14]. Thus, the findings of this analysis
may not be generalizable to MUPS patients without amal-
gam restorations nor to patients who do not attribute their
health complaints to dental amalgam.
In conclusion, the analyses indicate that GHC-index had
acceptable construct validity and internal consistency reli-
ability when used with patients with health complaints
attributed to amalgam restorations. In this respect, all out-
come measures have good discriminative power. The mean
change score as diagnostic test and other alternative meas-
ures of responsiveness suggest that the GHC-index is
responsive to change. The comparison with a validated
instrument – GBB-24 – support our conclusion. However,
firm conclusions cannot be made until our findings have
been confirmed in other studies using additional indicators
with larger sample size.
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